Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

For In depth Information Get Sample Copy of this Report at: https://bit.ly/2XqLfJr

Global Key Players:

Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.

Detailed Segmentation:

Global Pemetrexed Market, By Strength :
100 mg, 500 mg

Global Pemetrexed Market, By Distribution Channel:
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Global Pemetrexed Market, By Region:
North America,Europe,Asia Pacific,Latin America,Middle East,Africa

North America Is Expected To Hold Dominant Position, Owing To High Prevalence Of Non-Small Cell Lung Cancer And Its High Treatment Rate In The U.S.

According to Eli Lilly and Company’s annual report 2017, Alimta (pemetrexed) generated around 50% of its revenue from the U.S. Hence, North America is expected to be most conducive region for growth of the pemetrexed market, due to high prevalence of non-small cell lung cancer and high cost for its treatment.
For instance, according to the data published by the American Cancer Society in 2017, lung cancer (both small cell and non-small cell) is the second most common type of cancer in U.S and around 13% of all new cancers are lung cancer.

American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) would be diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC (68%), stage IIIA NSCLC (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).

Browse Research Report At: https://bit.ly/2SxECRP


Market Dynamics:

Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.
For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.

High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.
For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

Inquire Here Before Purchase of Research Report @ https://bit.ly/2NwV83S


About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]